Emerging therapy

Exosomes

Extracellular vesicles, MSC-derived EVs

The cell-free next step after stem cells, with genuinely interesting laboratory science — and, in children, almost no controlled clinical evidence at all.

Where it stands, condition by condition

The same therapy can be well supported for one problem and completely untested for another. This is the single most common place families are misled.

What it is

Exosomes are tiny membrane-wrapped packages that cells release to talk to each other. They carry proteins, lipids and small RNA molecules that can change how a receiving cell behaves.

The clinical idea is appealing: if stem cells mostly work by signalling rather than by replacing tissue, then perhaps you can give the signal without the cell — no living graft, no risk of unwanted growth, and a product that can be frozen and shipped.

That logic is sound. The problem is that “exosome” describes a biological object, not a medicine. Two vials with the same label can differ completely in cell source, purification method, particle count and cargo. There is no agreed potency test.

How it is meant to work

Delivered vesicles are taken up by cells in the injured area and are thought to shift microglia away from an inflammatory state, support surviving neurons and promote repair of the blood–brain barrier.

Nearly all of this is shown in cell culture and rodent models of stroke, hypoxic injury and traumatic brain injury, where results are often impressive.

Rodent brain injury models have predicted human benefit poorly for decades. A strong animal result is a reason to run a trial, not a reason to treat a child.

What has actually been tested

• Registered, controlled trials of exosome products in children with neurological conditions are very few. Most of what circulates publicly is laboratory work, animal studies, or clinic case reports with no comparison group.
• Case reports cannot separate treatment effect from natural recovery, from the rehabilitation given at the same time, or from parents' hopes shaping what they notice.
• Regulators have intervened in this space. In the United States the FDA issued a public safety notification about unapproved exosome products after patients were hospitalised with serious infections following treatment at a private clinic.
• Nothing about that warning says exosomes cannot work. It says the products being sold were not controlled medicines.

What we still do not know

• What dose means — particle number, protein content and biological potency do not track each other.
• Whether vesicles given into a vein reach the child's brain in useful quantity.
• What a second or tenth course does, since repeat dosing is standard commercial practice and untested.
• Long-term safety in a developing nervous system.

Where exosomes sit in European law — what it does and does not mean

In January 2025 the European Medicines Agency's Committee for Advanced Therapies settled a question that had been argued over for years. The scope section of its guideline on investigational advanced therapy medicinal products states:

Not substantially modified extracellular vesicles and cellular fragments originating from human cells or chemically synthesised therapeutic sequences do not fulfil the current definition of ATMPs and therefore the risk-based approach as laid out in Regulation (EC) No 1394/2007 does not apply.

EMA/CAT/22473/2025 — Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials. Adopted by CAT 6 December 2024 and CHMP 20 January 2025; in effect from 1 July 2025.

Read plainly, this is a clarification that helps development. Advanced therapy medicinal product — ATMP — is the category built for cell and gene therapies, and it carries a heavy, specialised apparatus with it. By confirming that minimally altered vesicles do not meet that definition, the guideline places them instead on the ordinary path for biological medicines, where biologics rules are the natural starting point. For a developer that is a workable route where there had been an unresolved argument.

So the short version often heard — exosomes are no longer treated like stem cell products, they can be developed as medicines — is broadly fair.

Three things that short version leaves out. First, the guideline does not define what counts as “substantially modified”, and that threshold decides whether the carve-out applies to a particular product. Second, engineered vesicles can fall back inside the advanced-therapy regime: where the cargo is intended to act on the recipient's genes, the product is a gene therapy. Third, there is still no vesicle-specific quality or non-clinical guidance from the EMA, the FDA or the WHO, so each product is assessed case by case against frameworks written for something else.

And the part that matters most if you are a parent rather than a developer: a route to develop a medicine is not a medicine. Classification answers the question “which rulebook applies?” — never “does this work?”. As of October 2026, no exosome or extracellular-vesicle product holds a marketing authorisation from the European Medicines Agency, the United States FDA or Australia's TGA, for any condition.

That is the question to put to a clinic citing this change: not whether exosomes have been reclassified — they have — but whether the product being offered to your child has an authorisation number. Today, none does.

More in this section